Assignee
APEXIGEN INC
US·9 granted patents·11 pending applications·70 citations·filing 2013–2023
Top patents by PatentIndex Score
20 records- 0198US9266956B2Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodiesAPEXIGEN INC·Filed 2015·Granted Feb 23, 2016·22 cites·28 claims
- 0296US8957193B2Polynucleotides encoding anti-CD40 antibodiesAPEXIGEN INC·Filed 2014·Granted Feb 17, 2015·21 cites·10 claims
- 0395US9556278B2Anti-CD40 antibodiesAPEXIGEN INC·Filed 2016·Granted Jan 31, 2017·9 cites·10 claims
- 0489US9994640B2Anti-CD40 antibodiesAPEXIGEN INC·Filed 2017·Granted Jun 12, 2018·6 cites·9 claims
- 0589US9676861B2Anti-CD40 antibodies and methods of useAPEXIGEN INC·Filed 2013·Granted Jun 13, 2017·9 cites·10 claims
- 0687US11001637B2Anti-CD40 antibodiesAPEXIGEN INC·Filed 2016·Granted May 11, 2021·2 cites·11 claims
- 0785US2024158523A1Anti-cd40 antibodies and methods of useAPEXIGEN INC·Filed 2023·Application pending·0 cites
- 0876US2022049005A1Anti-cd40 antibodies and methods of useAPEXIGEN INC·Filed 2021·Application pending·0 cites
- 0972US2022049006A1Anti-cd40 antibodies and methods of useAPEXIGEN INC·Filed 2021·Application pending·0 cites
- 1071US10259878B2Anti-RANKL antibodies and methods of useAPEXIGEN INC·Filed 2014·Granted Apr 16, 2019·1 cites·21 claims
- 1160US2018273630A1Anti-cd40 antibodies and methods of useAPEXIGEN INC·Filed 2018·Application pending·0 cites
- 1253US2019309080A1Anti-rankl antibodies and methods of useAPEXIGEN INC·Filed 2019·Application pending·0 cites
- 1352US9951136B2Anti-IL-6 receptor antibodies and methods of useAPEXIGEN INC·Filed 2014·Granted Apr 24, 2018·0 cites·17 claims
- 1450US2023340112A1Anti-sirpa antibodies and methods of useAPEXIGEN INC·Filed 2021·Application pending·0 cites
- 1549US2024336693A1Biomarkers for cd40 agonist therapyAPEXIGEN INC·Filed 2022·Application pending·0 cites
- 1648US2021139594A1Anti-cd40 antibodies in combination and methods of useAPEXIGEN INC·Filed 2020·Application pending·0 cites
- 1745US2022372154A1Anti-tnfr2 antibodies and methods of useAPEXIGEN INC·Filed 2020·Application pending·0 cites
- 1842US11078283B2Anti-PD-L1 antibodies and methods of useAPEXIGEN INC·Filed 2019·Granted Aug 3, 2021·0 cites·20 claims
- 1940US2018327496A1Anti-cd40 antibodies in combination and methods of useAPEXIGEN INC·Filed 2017·Application pending·0 cites
- 2038US2021139589A1Anti-vista antibodies and methods of useAPEXIGEN INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when APEXIGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →